Trial · NCT04891744
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
NCT04891744, Phase 1, Phase 2, Unknown, Li Zheng
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Selinexor in Combination With Thalidomide and Dexamethasone in RRMM. Trials, record NCT04891744. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04891744
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
- NCT number
- NCT04891744
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- Li Zheng
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor, Thalidomide, Dexamethasone
- First posted
- 2021-05-18
- Last updated
- 2021-05-18
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | Assessed from the date of first dose of study treatment until the date that PD assessed up to 12months | ORR in each arm: partial response (PR) + very good partial response (VGPR) + complete response (CR) |
| Secondary | Duration of Response (DOR) | 12 months | Duration from the first observation of at least PR to time of disease progression, or deaths due to disease progression, whichever occurs first. |
| Secondary | Disease Control Rate (DCR) | 12 months | Disease Control Rate (DCR=CBR+Stable Disease\[SD; for a minimum of 12 weeks\]) |
| Secondary | Progression-Free Survival (PFS) | 12 months | Duration from start of study treatment to PD or death (regardless of cause), whichever comes first |
| Secondary | Overall Survival (OS) | 12 months | The estimates of Kaplan-Meier |
| Secondary | Minimal Residual Disease (MRD) | 12 months | To evaluate the minimal residual disease in CR and sCR patients |
| Secondary | Clinical Benefit Rate (CBR) | 12 months | Clinical Benefit Rate (CBR=ORR+Minor Response \[MR\]) |
| Secondary | Number of Participants with Adverse Events | From first dose of study drug administration to end of treatment (up to 12 months) | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04891744
GET https://conductscience.org/api/trials/v1/NCT04891744/registered